title: Metformin may improve the prognosis of patients with pancreatic cancer.
abstract: BACKGROUND
  Pancreatic cancer risk is increased in patients with type 2 diabetes, while being reduced by metformin treatment. However, it is unclear whether metformin could be associated with clinical outcomes of patients with pancreatic cancer and concurrent type 2 diabetes.
  
  
  METHODS
  A pooled analysis of 4 publications including 1,429 patients was performed to investigate the association of metformin and overall survival(OS) in patients with pancreatic cancer and concurrent type 2 diabetes.
  
  
  RESULTS
  A borderline significant relative survival benefit was found in metformin treated patients compared with non-metformin treated patients (hazard ratio 0.80; 95% CI: 0.62-1.03).
  
  
  CONCLUSIONS
  These results suggest that further investigation is warranted of whether metformin may benefit the survival of patients with pancreatic cancer and concurrent type 2 diabetes.
authors.affiliation: The Department of Oncology, Nanjing Medical University Affiliated Wuxi Second Hospital, Jiangsu, China E-mail : zhangjiaweigrac@163.com.
authors.forename: Jia-Wei
authors.initials: JW
authors.lastname: Zhang
authors.forename: Qing
authors.initials: Q
authors.lastname: Sun
mesh_terms: D048909:Diabetes Complications / Q000188:drug therapy* / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D015201:Meta-Analysis as Topic; D008687:Metformin / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D015996:Survival Rate
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin